Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 10/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29386304 | 0.98 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL38150 | 0.98 | SLC5A2 (0.53) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL16608734 | 0.87 | PKM (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL3680232 | 0.87 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL10211827 | 0.86 | SLC5A2 (0.44) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL38651021 | 0.85 | L3MBTL1 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL27368089 | 0.85 | L3MBTL1 (0.44) | SLC5A2SLC5A1 | |
| SCHEMBL15397883 | 0.84 | HTR2A (0.42) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL3680551 | 0.84 | SLC5A2 (0.52) | SLC5A2SLC5A1ADRA2ASLC5A11ALDH1A1 | |
| SCHEMBL18418928 | 0.83 | DHFR (0.46) | SLC5A2SLC5A1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2020-07-07 | — | — | US | disclosed |
| US-20180346502-A1 | Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof | EMMENNAR PHARMA PRIVATE LIMITED (IN) | 2018-12-06 | — | — | US | disclosed |
| EP-2776449-B1 | PROCESS FOR THE PREPARATION OF BETA-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN LTD (TW) | 2017-08-02 | — | — | EP | disclosed |
| US-8952139-B2 | Process for the preparation of β-C-aryl glucosides | SCINOPHARM TAIWAN, LTD (TW) | 2015-02-10 | — | — | US | disclosed |
| EP-2776449-A2 | PROCESS FOR THE PREPARATION OF beta-C-ARYL GLUCOSIDES | Scinopharm Taiwan Ltd. (TW) | 2014-09-17 | — | — | EP | disclosed |
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SCINOPHARM TAIWAN, LTD. (TW) | 2014-05-08 | — | — | US | disclosed |
| WO-2013068850-A2 | PROCESS FOR THE PREPARATION OF β-C-ARYL GLUCOSIDES | SCINOPHARM TAIWAN, LTD. (NA) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128595-A1 | Process for the Preparation of ß-C-Aryl Glucosides | SLC5A2, SLC5A1, UGGT1 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 672/4885 |
| US-10703772-B2 | Processes for the preparation of SGLT-2 inhibitors, intermediates thereof | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2409/4885 |
| US-20180346502-A1 | Processes for the Preparation of SGLT-2 Inhibitors, Intermediates Thereof | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.